Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
JNJ
$204.39
$-1.36
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Next Earnings
2026-01-11
Beta
0.333
Average Volume
8435006
Market Cap
492435825898
Last Dividend
5.14
CIK
0000200406
ISIN
US4781601046
CUSIP
478160104
CEO
Joaquin Duato
Sector
Healthcare
Industry
Drug Manufacturers - General
Full Time Employees
138100
IPO Date
1943-01-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips | The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%. | Forbes | 2026-01-11 07:40:35 |
| RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer | Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were also seen in patients with liver metastases, who often face poorer outcomes with this disease RARITAN, N.J., Jan. 10, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. | PRNewsWire | 2026-01-10 10:00:00 |
| January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy | Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could deliver an average 23.55% net gain by January 2027, with varying risk profiles. Yield-based strategies favor underdogs; price drops or dividend hikes could bring more Dow Dogs into fair-value territory for income-focused investors. | Seeking Alpha | 2026-01-10 09:52:01 |
| Johnson & Johnson $JNJ Shares Sold by Cerity Partners LLC | Cerity Partners LLC lowered its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 1.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,782,644 shares of the company's stock after selling 28,920 shares during the period. Johnson and | Defense World | 2026-01-10 03:40:58 |
| Market Today: Meta taps nuclear; GM books $6B EV charge | Stock News California billionaire tax splits tech leaders: Nvidia (NVDA) CEO Jensen Huang said he's âfineâ with a proposed one-time 5% California wealth tax | GuruFocus | 2026-01-09 17:35:00 |
| J&J Finds Middle Ground in Washington | Johnson and Johnson (JNJ) is making a very Washington style trade off. The company said it has reached an agreement with the Trump administration to lower drug pr | GuruFocus | 2026-01-09 12:49:00 |
| J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve | JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing. | Zacks Investment Research | 2026-01-09 11:55:24 |
| 2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio | AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers. | The Motley Fool | 2026-01-09 11:45:00 |
| Cramer's Mad Dash: Johnson & Johnson | CNBC's Jim Cramer delivers his daily Mad Dash. | CNBC Television | 2026-01-09 09:59:37 |
| First Look: GM's $7.1B EV Charge, Paramount's $30 WBD Bid | Stock News xAI under fire over Grok image edits: Elon Musk's xAI (private) restricted Grok's image generation/editing on X to paying users after the tool was us | GuruFocus | 2026-01-09 07:38:00 |
| Breakfast News: TSM Defies Bubble Fears | TSM enjoys revenue surge, Nvidia adds CMO for brand recognition, jobs report due, and more | Fool - Investing News | 2026-01-09 07:30:00 |
| Johnson & Johnson Strikes Deal With White House to Lower Drug Prices | Trump administration secures deal with Johnson & Johnson to reduce price of some medicines | Barrons | 2026-01-09 05:10:00 |
| Johnson & Johnson Secures Tariff Exemption Deal In Exchange For Drug Price Cuts | Johnson and Johnson struck a deal with the Trump administration to lower drug prices for U.S. consumers in exchange for exemptions from tariffs. | Benzinga | 2026-01-09 03:27:31 |
| Almanack Investment Partners LLC. Has $2.42 Million Position in Johnson & Johnson $JNJ | Almanack Investment Partners LLC. grew its holdings in Johnson and Johnson (NYSE: JNJ) by 29.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,074 shares of the company's stock after buying an additional 2,985 shares during the quarter. Almanack Investment | Defense World | 2026-01-09 03:04:52 |
| Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices | The agreement provides Johnson & Johnson's pharmaceutical products an exemption from tariffs, the company said. | WSJ | 2026-01-08 21:33:00 |
| Johnson & Johnson reaches deal with US government to lower drug prices | Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trump's administration to cut drug prices for Americans in exchange for exemptions from U.S. tariffs. | Reuters | 2026-01-08 20:43:21 |
| Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments | NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company's pharmaceutical products an exemption from tariffs1. “Today's agreement shows that when. | Business Wire | 2026-01-08 20:24:00 |
| J&J's Innovative Medicine Segment in Q4: Here's What to Watch | JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds. | Zacks Investment Research | 2026-01-08 10:01:04 |
| CWA Asset Management Group LLC Sells 21,081 Shares of Johnson & Johnson $JNJ | CWA Asset Management Group LLC decreased its holdings in Johnson and Johnson (NYSE: JNJ) by 17.4% during the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 99,944 shares of the company's stock after selling 21,081 shares during the quarter. Johnson and Johnson accounts | Defense World | 2026-01-08 05:38:43 |
| Daymark Wealth Partners LLC Has $39.44 Million Position in Johnson & Johnson $JNJ | Daymark Wealth Partners LLC lifted its stake in Johnson and Johnson (NYSE: JNJ) by 6.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 212,719 shares of the company's stock after acquiring an additional 13,662 shares during the quarter. Johnson and Johnson makes | Defense World | 2026-01-08 05:38:43 |
| Johnson & Johnson $JNJ Shares Acquired by D.A. Davidson & CO. | D.A. Davidson and CO. lifted its stake in shares of Johnson and Johnson (NYSE: JNJ) by 1.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 723,906 shares of the company's stock after purchasing an additional 9,671 shares during | Defense World | 2026-01-08 04:52:49 |
| JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus | J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III. | Zacks Investment Research | 2026-01-07 12:50:30 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. | Zacks Investment Research | 2026-01-07 09:55:20 |
| Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration | NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen. “We have taken learnings from Johnson & Johnson's 140 years in surge. | Business Wire | 2026-01-07 08:00:00 |
| The Smartest Dividend Stocks to Buy With $3,000 Right Now | Contrary to a common assumption, McDonald's main business isn't as a fast-food restaurant chain. After a lengthy dry spell, Johnson & Johnson is starting to fire on all cylinders again. | The Motley Fool | 2026-01-07 03:35:00 |
| Asset Management One Co. Ltd. Buys 47,524 Shares of Johnson & Johnson $JNJ | Asset Management One Co. Ltd. grew its stake in shares of Johnson and Johnson (NYSE: JNJ) by 3.9% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,256,031 shares of the company's stock after acquiring an additional 47,524 shares during the period. Johnson and Johnson | Defense World | 2026-01-07 03:29:01 |
| JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors? | J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion. | Zacks Investment Research | 2026-01-06 12:55:23 |
| Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study | The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing SLE is one of the most prevalent and debilitating autoantibody diseases, causing one's own immune system to mistakenly attack various tissues, which can lead to potentially life-threatening systemic organ damage Based on these positive topline results, the company plans to initiate a Phase 3 program for nipocalimab in SLE SPRING HOUSE, Pa., Jan. 6, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 program. | PRNewsWire | 2026-01-06 08:03:00 |
| Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma | Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 | GlobeNewsWire | 2026-01-06 06:52:00 |
| Forget Venezuela Hype: Jim Cramer Explains Why You Missed Oil Trade And What Stocks To Buy Instead | Jim Cramer warns against the Venezuela oil trade. Find out which undervalued bank and pharma stocks he says to buy for 2026 instead. | Benzinga | 2026-01-06 06:13:56 |
| The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson | Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026. | Zacks Investment Research | 2026-01-06 05:41:09 |
| Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note | In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $204.31, denoting a -1.47% move from the preceding trading day. | Zacks Investment Research | 2026-01-05 18:45:51 |
| 3 High-Yielding Dividend Kings to Buy in January for Safe Passive Income in 2026 and Beyond | Coca-Cola raised its dividend by 5.2% in 2025, extending its streak to 63 straight years. Kimberly-Clark's 3.3% raise last year pushed its dividend growth streak to 53 consecutive years. | The Motley Fool | 2026-01-05 10:18:00 |
| Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026 | LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026. | Zacks Investment Research | 2026-01-05 08:45:32 |
| Johnson & Johnson $JNJ Holdings Lifted by First Pacific Financial | First Pacific Financial increased its holdings in Johnson and Johnson (NYSE: JNJ) by 22.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,464 shares of the company's stock after acquiring an additional 4,331 shares during the period. | Defense World | 2026-01-05 07:00:43 |
| Econ Financial Services Corp Sells 4,074 Shares of Johnson & Johnson $JNJ | Econ Financial Services Corp trimmed its position in Johnson and Johnson (NYSE: JNJ) by 25.5% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,888 shares of the company's stock after selling 4,074 shares during the period. Econ Financial Services Corp's holdings in Johnson | Defense World | 2026-01-05 07:00:43 |
| Johnson & Johnson $JNJ Shares Purchased by Golden State Equity Partners | Golden State Equity Partners grew its position in shares of Johnson and Johnson (NYSE: JNJ) by 20.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,491 shares of the company's stock after purchasing an additional 3,654 shares during the period. Johnson | Defense World | 2026-01-05 05:34:45 |
| 3,364 Shares in Johnson & Johnson $JNJ Bought by Financial Consulate Inc. | Financial Consulate Inc. bought a new stake in Johnson and Johnson (NYSE: JNJ) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,364 shares of the company's stock, valued at approximately $624,000. A number of other institutional investors | Defense World | 2026-01-04 05:26:51 |
| Ninety One SA PTY Ltd Cuts Stake in Johnson & Johnson $JNJ | Ninety One SA PTY Ltd lessened its stake in Johnson and Johnson (NYSE: JNJ) by 22.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,770 shares of the company's stock after selling 21,921 shares during the quarter. | Defense World | 2026-01-04 05:26:51 |
| Johnson & Johnson $JNJ is Ninety One UK Ltd’s 7th Largest Position | Ninety One UK Ltd reduced its stake in Johnson and Johnson (NYSE: JNJ) by 5.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,640,116 shares of the company's stock after selling 376,048 shares during the period. Johnson | Defense World | 2026-01-04 05:26:50 |
| Delta Investment Management LLC Acquires 5,284 Shares of Johnson & Johnson $JNJ | Delta Investment Management LLC increased its holdings in Johnson and Johnson (NYSE: JNJ) by 63.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,674 shares of the company's stock after acquiring an additional 5,284 shares during the period. Delta Investment | Defense World | 2026-01-04 04:06:55 |
| 2 Healthcare Stocks to Buy in a Bear Market | Johnson & Johnson and Abbott Laboratories are diversified healthcare companies with attractive prospects. Both have raised their dividends for over 50 consecutive years. | The Motley Fool | 2026-01-03 09:15:00 |
| 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (January 2026) | This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.3%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%. | Seeking Alpha | 2026-01-03 08:00:00 |
| Johnson & Johnson $JNJ Stock Position Increased by VIRGINIA RETIREMENT SYSTEMS ET Al | VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in Johnson and Johnson (NYSE: JNJ) by 12.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,158,903 shares of the company's stock after purchasing an additional 127,100 shares during the quarter. | Defense World | 2026-01-03 05:37:05 |
| Dividend Growers: 3 Stocks That Could Be Worth $1 Million in 36 Years. | NextEra Energy has grown its dividend at a 10% compound annual rate over the past 20 years. Realty Income has increased its dividend for more than 30 consecutive years. | The Motley Fool | 2026-01-03 05:30:00 |
| Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites | The 10 highest paying dividend stocks in the Dow Jones Industrial Average offer yields from 2.5% to 6.8%. A look at the Dogs of the Dow. | Benzinga | 2026-01-02 17:06:40 |
| Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers | Investors may be surprised to learn which Dow Jones Industrial Average stocks were the best and worst performing in 2025. Here's the list. | Benzinga | 2026-01-02 16:17:22 |
| Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026 | NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company's common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare in. | Business Wire | 2026-01-02 08:00:00 |
| First Look: Futures Climb, FTSE 10,000, BYD Tops Tesla | Stock News U.S. futures rise on first trading day: Tech leaders Nvidia (NVDA), Palantir (PLTR), Apple (AAPL), Alphabet (GOOGL), and Microsoft (MSFT) advanced pr | GuruFocus | 2026-01-02 07:38:00 |
| Ascent Group LLC Cuts Stock Position in Johnson & Johnson $JNJ | Ascent Group LLC decreased its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 8.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,449 shares of the company's stock after selling 5,723 shares during the period. Ascent Group LLC's | Defense World | 2026-01-02 03:27:02 |
| Want Decades of Passive Income? 2 Stocks to Buy Right Now | These businesses are profitable with durable competitive advantages. Johnson & Johnson is one of the leading pharmaceutical companies. | The Motley Fool | 2026-01-01 08:23:00 |
| Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It? | When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? | Zacks Investment Research | 2025-12-31 10:31:19 |
| Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock | Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. | Zacks Investment Research | 2025-12-31 10:00:50 |
| The Big 3: JNJ, SNDK, TWLO | Healthcare, storage chips, and software adding AI integration take the focus of Tuesday's Big 3. Jenny Horne and Rick Ducat turn to technical analysis in Johnson & Johnson (JNJ), SanDisk (SNDK), and Twilio (TWLO). | Schwab Network | 2025-12-30 13:31:10 |
| Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now | CNBC's "Mad Money" host is waving the yellow flag. | Investopedia | 2025-12-30 09:55:59 |
| Got $500? 3 Dividend-Paying Healthcare Stocks to Buy and Hold Forever | Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device maker that's nearing Dividend King status. | The Motley Fool | 2025-12-30 09:15:00 |
| 3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains | Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns. | Zacks Investment Research | 2025-12-30 09:01:12 |
| More Upside For JNJ Stock In 2026? | Johnson & Johnson has just undergone its most significant transformation in decades. In 2023, the consumer health segment was spun off as Kenvue. | Forbes | 2025-12-30 05:05:23 |
| Dogs of the Dow Had a Strong Year as Dividends Paid Off | High-yielding Dow stocks outperformed the broader market this year. Will new Dow dogs Home Depot, Nike, and UnitedHealth keep the streak going? | Barrons | 2025-12-29 13:56:00 |
| Top 5 High-Yield S&P 500 Stocks to Buy for 2026 | High-yield S&P 500 stocks are gaining traction for 2026 as AI investment accelerates and investors seek income amid trade and geopolitical uncertainty. | Zacks Investment Research | 2025-12-29 13:31:14 |
| Could These 3 "Recession-Proof" Dividend Stocks Surge 100% by 2031? | Microsoft is a terrific growth stock with an excellent dividend program. Johnson & Johnson and Coca-Cola are both outstanding dividend payers. | The Motley Fool | 2025-12-29 11:23:00 |
| Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies | NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. (“Halda”), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. “This strategic milestone underscores our commitment to r. | Business Wire | 2025-12-29 08:00:00 |
| HBK Sorce Advisory LLC Sells 4,661 Shares of Johnson & Johnson $JNJ | HBK Sorce Advisory LLC decreased its position in shares of Johnson and Johnson (NYSE: JNJ) by 8.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,083 shares of the company's stock after selling 4,661 shares during the quarter. HBK Sorce Advisory | Defense World | 2025-12-29 05:21:18 |
| Johnson & Johnson (NYSE:JNJ) Receives Consensus Recommendation of “Moderate Buy” from Brokerages | Shares of Johnson and Johnson (NYSE: JNJ - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-seven brokerages that are presently covering the firm, MarketBeat reports. Nine investment analysts have rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and four have assigned a strong buy recommendation | Defense World | 2025-12-28 02:14:53 |
| Market Today: Metals Rally; Nvidia-Groq Deal Lifts NVDA | Stock News Metals surge as stocks hold near records: Gold and silver hit fresh records while major U.S. indexes closed little changed; mining shares including F | GuruFocus | 2025-12-26 17:36:00 |
| Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth? | JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade. | Zacks Investment Research | 2025-12-26 09:26:06 |
| Johnson & Johnson halts mid-stage trial of experimental eczema drug | Johnson & Johnson said on Friday it has discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis, after it failed to meet efficacy goals in an interim analysis. | Reuters | 2025-12-26 08:13:24 |
| Dogs of the Dow Beat the Market in 2025 — Here's the Smarter 4-Stock Play for 2026 | Keeping things simple when investing is often best, which is why buying an index fund can be the optimal strategy. | 24/7 Wall Street | 2025-12-25 09:50:50 |
| Coho Partners Ltd. Sells 133,505 Shares of Johnson & Johnson $JNJ | Coho Partners Ltd. reduced its stake in shares of Johnson and Johnson (NYSE: JNJ) by 43.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,469 shares of the company's stock after selling 133,505 shares during the quarter. Johnson | Defense World | 2025-12-24 06:22:42 |
| BigSur Wealth Management LLC Lowers Stock Holdings in Johnson & Johnson $JNJ | BigSur Wealth Management LLC cut its stake in shares of Johnson and Johnson (NYSE: JNJ) by 33.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,532 shares of the company's stock after selling 2,800 shares during the quarter. BigSur Wealth | Defense World | 2025-12-24 05:15:00 |
| Baldwin Wealth Partners LLC MA Sells 3,828 Shares of Johnson & Johnson $JNJ | Baldwin Wealth Partners LLC MA reduced its holdings in Johnson and Johnson (NYSE: JNJ) by 5.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 67,858 shares of the company's stock after selling 3,828 shares during the quarter. Baldwin Wealth Partners LLC | Defense World | 2025-12-24 05:15:00 |
| Johnson & Johnson Faces Legal Setback with $1.5 Billion Verdict | Johnson and Johnson (JNJ) confronts a new legal challenge after a $1.5 billion verdict was awarded to Cherie Craft, a Maryland woman who claimed the company's tal | GuruFocus | 2025-12-23 13:14:00 |
| Top 5 High-Yield S&P 500 Stocks to Buy for Reliable Returns in 2026 | High-yield S&P 500 stocks IVZ, JNJ, NI, BG and MS offer steady income, compounding returns and portfolio stability as moderate growth and easing inflation shape 2026. | Zacks Investment Research | 2025-12-23 12:16:08 |
| J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling | The plaintiff's law firm said was the largest-ever sum awarded against J&J for a single plaintiff. | New York Post | 2025-12-23 11:41:23 |
| JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis | Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition. | Zacks Investment Research | 2025-12-23 11:26:13 |
| Stormy 2026? 3 Defensive Stocks to Weather a Recession | TPB, JNJ and NEE highlight how defensive stocks can offer stability and steady growth potential amid rising uncertainty for 2026. | Zacks Investment Research | 2025-12-23 11:06:08 |
| 5 Big Drug Stocks That May Continue to Outperform in 2026 | Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026. | Zacks Investment Research | 2025-12-23 09:51:10 |
| The Dividend King Buy-and-Hold Strategy That Can Surge 100% in 10 Years | Coca-Cola has increased its dividend for 63 straight years. Johnson & Johnson has matched Coca-Cola's dividend growth streak. | The Motley Fool | 2025-12-23 07:45:00 |
| Clarius Group LLC Has $3.42 Million Stock Holdings in Johnson & Johnson $JNJ | Clarius Group LLC decreased its position in Johnson and Johnson (NYSE: JNJ) by 25.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,422 shares of the company's stock after selling 6,436 shares during the quarter. Clarius Group LLC's holdings in | Defense World | 2025-12-23 05:20:50 |
| J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised) | JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications. | Zacks Investment Research | 2025-12-23 04:56:06 |
| Johnson & Johnson Hit With Record $1.5 Billion US Verdict Over Talc Cancer Claim | Baltimore jury awards $1.5 billion against Johnson and Johnson in record talc-asbestos mesothelioma verdict; company plans to appeal. | Benzinga | 2025-12-23 02:50:09 |
| J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award | A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company's talc-based products caused her peritoneal mesothelioma, a form of cancer. | Reuters | 2025-12-23 00:34:03 |
| Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder | BALTIMORE--(BUSINESS WIRE)--A Baltimore city jury has returned a verdict in favor of Cherie A. Craft, awarding her over $1.5 billion after finding that Johnson & Johnson and its subsidiaries exposed her to asbestos through talc-based personal care products and caused her to develop peritoneal malignant mesothelioma, an incurable cancer. The verdict is believed to be the largest ever returned against Johnson & Johnson for a single plaintiff. Ms. Craft, a mother and the founder, CEO and e. | Business Wire | 2025-12-22 23:15:00 |
| J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play | J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution, new drugs and pipeline progress support bullish momentum. | Zacks Investment Research | 2025-12-22 12:26:06 |
| Perpetual Ltd Sells 4,180 Shares of Johnson & Johnson $JNJ | Perpetual Ltd trimmed its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 10.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,430 shares of the company's stock after selling 4,180 shares during the period. Perpetual Ltd's holdings in | Defense World | 2025-12-22 07:18:42 |
| Rydar Equities Inc. Sells 3,178 Shares of Johnson & Johnson $JNJ | Rydar Equities Inc. cut its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 55.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,515 shares of the company's stock after selling 3,178 shares during the quarter. Rydar Equities | Defense World | 2025-12-22 06:36:44 |
| Johnson & Johnson $JNJ Shares Purchased by Foster Victor Wealth Advisors LLC | Foster Victor Wealth Advisors LLC boosted its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 3.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,706 shares of the company's stock after buying an additional 2,997 shares | Defense World | 2025-12-22 05:56:46 |
| Cyndeo Wealth Partners LLC Increases Stock Position in Johnson & Johnson $JNJ | Cyndeo Wealth Partners LLC raised its stake in Johnson and Johnson (NYSE: JNJ) by 63.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,832 shares of the company's stock after acquiring an additional 40,238 shares during the period. | Defense World | 2025-12-22 05:24:51 |
| Johnson & Johnson $JNJ Shares Acquired by Fairvoy Private Wealth LLC | Fairvoy Private Wealth LLC boosted its position in Johnson and Johnson (NYSE: JNJ) by 245.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,179 shares of the company's stock after purchasing an additional 3,680 shares during the quarter. Fairvoy Private Wealth LLC's | Defense World | 2025-12-22 05:24:51 |
| Bartlett & CO. Wealth Management LLC Has $47.19 Million Stake in Johnson & Johnson $JNJ | Bartlett and CO. Wealth Management LLC lessened its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 5.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 254,517 shares of the company's stock after selling 13,578 shares during the period. | Defense World | 2025-12-22 03:26:51 |
| Brady Family Wealth LLC Sells 2,471 Shares of Johnson & Johnson $JNJ | Brady Family Wealth LLC cut its stake in shares of Johnson and Johnson (NYSE: JNJ) by 7.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 29,349 shares of the company's stock after selling 2,471 shares during the period. Johnson | Defense World | 2025-12-21 05:08:42 |
| Astoria Portfolio Advisors LLC. Lowers Holdings in Johnson & Johnson $JNJ | Astoria Portfolio Advisors LLC. lowered its position in Johnson and Johnson (NYSE: JNJ) by 43.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,801 shares of the company's stock after selling 3,652 shares during the quarter. Astoria Portfolio | Defense World | 2025-12-21 03:44:42 |
| Why a Minnesota Jury Ordered Johnson & Johnson To Pay $65.5 Million in Damages | Johnson and Johnson has been directed to pay $65.6 million to a Minnesota woman who was diagnosed with cancer following the use of their talcum powder. | Benzinga | 2025-12-20 16:41:17 |
| What Retirement Really Looks Like With $2.5 Million in Savings | For as long as most of us can remember, the idea of retiring with $2.5 million in the "bank," is something of a dream. The belief that this amount of money would guarantee decades of worry-free living feels like all of the stars aligning after decades of hard work, disciplined savings, and investing, and the... What Retirement Really Looks Like With $2.5 Million in Savings. | 247 Wallst | 2025-12-20 10:31:56 |
| Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder | A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the lining of her lungs. | New York Post | 2025-12-20 03:55:05 |
| Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal | Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing. | Benzinga | 2025-12-20 01:38:01 |
| Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson | ST. PAUL, Minn.--(BUSINESS WIRE)--A Minnesota jury awarded $65.5 million to a 37-year-old mother of three minor children after finding in her favor in a lawsuit against Johnson & Johnson, concluding that the company's talc products exposed her to asbestos and contributed to her developing mesothelioma, a cancer of the lining of the lungs. The verdict follows a 13-day trial in Ramsey County District Court, where jurors heard evidence that Johnson & Johnson sold and marketed talc-based co. | Business Wire | 2025-12-19 17:54:00 |
| First Look: Oracle leads TikTok JV, CPI cools, Nike drops | Stock News TikTok inks U.S. spinoff deal: Oracle (ORCL) and partners Silver Lake and MGX will take major stakes in a new TikTok U.S. venture, with U.S. data hos | GuruFocus | 2025-12-19 07:37:00 |
| Johnson & Johnson $JNJ Shares Bought by Czech National Bank | Czech National Bank grew its stake in shares of Johnson and Johnson (NYSE: JNJ) by 4.0% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 611,668 shares of the company's stock after buying an additional 23,539 shares during the period. Johnson and Johnson | Defense World | 2025-12-19 05:28:53 |
| Johnson & Johnson $JNJ Shares Sold by Chesley Taft & Associates LLC | Chesley Taft and Associates LLC lowered its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 2.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 198,127 shares of the company's stock after selling 5,244 shares during the period. | Defense World | 2025-12-19 04:48:43 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4/A | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-11 | 2025-12-11 | View Filing |
| 4 | 2025-12-01 | 2025-12-01 | View Filing |
| 4 | 2025-12-01 | 2025-12-01 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 13F-HR | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G/A | 2025-10-22 | 2025-10-22 | View Filing |
| 10-Q | 2025-10-22 | 2025-10-22 | View Filing |
| 4 | 2025-10-20 | 2025-10-20 | View Filing |
| 8-K | 2025-10-14 | 2025-10-14 | View Filing |
| 3 | 2025-09-15 | 2025-09-15 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-11 | 2025-09-11 | View Filing |
| 8-K | 2025-09-09 | 2025-09-08 | View Filing |
| 4 | 2025-09-05 | 2025-09-05 | View Filing |
| 4 | 2025-09-03 | 2025-09-03 | View Filing |
| N-PX | 2025-08-26 | 2025-08-26 | View Filing |
| 4 | 2025-08-25 | 2025-08-25 | View Filing |
| 4 | 2025-08-18 | 2025-08-18 | View Filing |
| 10-Q | 2025-07-24 | 2025-07-24 | View Filing |
| 13F-HR | 2025-07-22 | 2025-07-22 | View Filing |
| 4 | 2025-07-18 | 2025-07-18 | View Filing |
| 8-K | 2025-07-16 | 2025-07-16 | View Filing |
| 3 | 2025-07-08 | 2025-07-08 | View Filing |
| 11-K | 2025-06-24 | 2025-06-23 | View Filing |
| 11-K | 2025-06-24 | 2025-06-23 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 8-K | 2025-06-10 | 2025-06-10 | View Filing |
| SD | 2025-05-28 | 2025-05-28 | View Filing |
| 13F-HR | 2025-05-07 | 2025-05-07 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 8-K | 2025-04-30 | 2025-04-30 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 4 | 2025-04-28 | 2025-04-28 | View Filing |
| 10-Q | 2025-04-23 | 2025-04-23 | View Filing |
| PX14A6G | 2025-04-23 | 2025-04-23 | View Filing |
| 8-K | 2025-04-15 | 2025-04-15 | View Filing |
| 8-K | 2025-04-03 | 2025-04-03 | View Filing |
| PX14A6G | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-03-19 | 2025-03-19 | View Filing |
| DEFA14A | 2025-03-12 | 2025-03-12 | View Filing |
| ARS | 2025-03-12 | 2025-03-12 | View Filing |
| DEF 14A | 2025-03-12 | 2025-03-12 | View Filing |
| DFAN14A | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 5 | 2025-02-28 | 2025-02-28 | View Filing |
| CERT | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 8-A12B | 2025-02-26 | 2025-02-26 | View Filing |
| 8-K | 2025-02-26 | 2025-02-26 | View Filing |
| DFAN14A | 2025-02-25 | 2025-02-25 | View Filing |
| 424B2 | 2025-02-21 | 2025-02-21 | View Filing |
| 8-K | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 424B2 | 2025-02-19 | 2025-02-19 | View Filing |
| FWP | 2025-02-19 | 2025-02-19 | View Filing |
| 424B5 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| 4 | 2025-02-18 | 2025-02-18 | View Filing |
| FWP | 2025-02-18 | 2025-02-18 | View Filing |
| 424B5 | 2025-02-18 | 2025-02-18 | View Filing |
| 10-K | 2025-02-13 | 2025-02-13 | View Filing |
| 13F-HR | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-12 | 2025-02-12 | View Filing |
| 4 | 2025-02-12 | 2025-02-12 | View Filing |
| 4 | 2025-02-12 | 2025-02-12 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Choppiness Index Strategy | 11.85% | 1 | 969 | 0.01 | 0.12 | 7.21 |
| Volume Weighted Momentum Strategy | 10.01% | 1.01 | 20 | 0.02 | 0.21 | 5.37 |
| Neural Forcast | 9.91% | 1 | 1254 | 0 | 0.06 | 5.27 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxx | xxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |